Blatchford Paul, Stoklosinski Halina, Eady Sarah, Wallace Alison, Butts Christine, Gearry Richard, Gibson Glenn, Ansell Juliet
The New Zealand Institute for Plant & Food Research Limited, Private Bag 11600, Palmerston North 4442, New Zealand.
The New Zealand Institute for Plant & Food Research Limited, Private Bag 4704, Lincoln 8140, New Zealand.
J Nutr Sci. 2017 Oct 12;6:e52. doi: 10.1017/jns.2017.52. eCollection 2017.
This study investigated the impact of ACTAZIN™ green (2400 and 600 mg) and Livaux™ (2400 mg) gold kiwifruit supplements on faecal microbial composition and metabolites in healthy and functionally constipated (FC) participants. The participants were recruited into the healthy group ( 20; one of whom did not complete the study) and the FC group ( 9), each of whom consumed all the treatments and a placebo (isomalt) for 4 weeks in a randomised cross-over design interspersed with 2-week washout periods. Modification of faecal microbiota composition and metabolism was determined by 16S rRNA gene sequencing and GC, and colonic pH was calculated using SmartPill wireless motility capsules. A total of thirty-two taxa were measured at greater than 1 % abundance in at least one sample, ten of which differed significantly between the baseline healthy and FC groups. Specifically, Bacteroidales and spp. were significantly more abundant ( < 0·05) in the healthy group and taxa including Ruminococcaceae, spp. and spp. were significantly more abundant ( < 0·05) in the FC group. In the FC group, abundance significantly increased ( = 0·024) from 3·4 to 7·0 % following Livaux™ supplementation, with eight of the nine participants showing a net increase. Lower proportions of are often associated with gastrointestinal disorders. The discovery that Livaux™ supplementation increased abundance offers a potential strategy for improving gut microbiota composition, as is a butyrate producer and has also been shown to exert anti-inflammatory effects in many studies.
本研究调查了ACTAZIN™绿色（2400毫克和600毫克）和Livaux™（2400毫克）金奇异果补充剂对健康和功能性便秘（FC）参与者粪便微生物组成和代谢物的影响。参与者被招募到健康组（20人；其中1人未完成研究）和FC组（9人），每组在随机交叉设计中食用所有治疗药物和安慰剂（异麦芽酮糖醇）4周，中间穿插2周的洗脱期。通过16S rRNA基因测序和气相色谱法测定粪便微生物群组成和代谢的变化，并使用SmartPill无线动力胶囊计算结肠pH值。在至少一个样本中，共测量了32个丰度大于1%的分类群，其中10个在基线健康组和FC组之间存在显著差异。具体而言，拟杆菌目和某些菌属在健康组中显著更为丰富（P<0·05），而包括瘤胃球菌科、某些菌属和某些菌属在内的分类群在FC组中显著更为丰富（P<0·05）。在FC组中，补充Livaux™后，某菌属的丰度从3·4%显著增加到7·0%（P = 0·024），9名参与者中有8名显示净增加。某菌属比例较低通常与胃肠道疾病有关。补充Livaux™会增加某菌属丰度这一发现为改善肠道微生物群组成提供了一种潜在策略，因为该菌属是丁酸盐产生菌，并且在许多研究中也已显示具有抗炎作用。
